LNC-003 / Rebus - LARVOL DELTA

A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer. (PubMed, Eur J Nucl Med Mol Imaging) - P=N/A | "This phase 1 trial revealed that the MTD of [Lu]Lu-LNC1003 is 1.85 GBq. The treatment with multiple cycles at the dose of 1.11 GBq /cycle and 1.85 GBq /cycle was well tolerated. [Lu]Lu-LNC1003 has higher tumor effective doses in bone and lymph nodes metastases while the absorbed dose in the red bone marrow should be closely monitored in future treatment studies with higher doses and multiple cycles. The frequency of administration also needs to be further explored to assess the efficacy and side effects of [Lu]Lu-LNC1003 treatment."

Journal • Metastases • P1 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Development of [Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression. (PubMed, Eur J Nucl Med Mol Imaging) - "In this study, [Lu]Lu-LNC1003 was successfully synthesized with high radiochemical purity and stability. High binding affinity and PSMA targeting specificity were identified in vitro and in vivo. With greatly enhanced tumor uptake and retention, [Lu]Lu-LNC1003 has the potential to improve therapeutic efficacy using significantly lower dosages and less cycles of Lu that promises clinical translation to treat prostate cancer with various levels of PSMA expression."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1